Search PubMed⌕ Search

Biomedical subjects

A Bot

Publications and source records attributed to A Bot.

14 recordsLinked to original sources
PubMed1992

Growth hormone treatment in Turner syndrome accelerates growth and skeletal maturation. Dutch Growth Hormone Working Group.

Sixteen girls with Turner syndrome (TS) were treated for 4 years with biosynthetic growth hormone (GH). The dosage was 4 IU/m2 body surface s.c. per day over the first 3 years. In the 4th year the dosage was increased to 6 IU/m2 per day in the 6 girls with a poor height increment and in 1 girl oxandrolone was added. Ethinyl oestradiol was added after the age of 13. Mean (SD) growth velocities were 3.4 (0.9), 7.2 (1.7), 5.3 (1.3), 4.3 (2.0) and 3.6 (1.5) cm/year before and in the 1st, 2nd, 3rd and 4th year of treatment. Skeletal maturation advanced faster than usual in Turner patients especially in the younger children. Although the mean height prediction increased by 5.6 cm and 11 of the 16 girls have now exceeded their predicted height, the height of the 4 girls who stopped GH treatment exceeded the predicted adult height by only 0 to 3.4 cm.

Adolescent↗
PubMed1992

Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group.

A multicenter dose-response study evaluated the effect of two different doses of biosynthetic GH on auxological and biochemical parameters in 38 prepubertal children with GH deficiency (GHD). Twenty-one were newly diagnosed, while 17 transfer patients had been on GH treatment for at least 1 yr before the study. New and transfer patients alike were treated with either 2 or 4 IU GH/m2.day sc. At evaluation all new patients had completed 1 yr of treatment, while transfers had completed 2 yr of treatment under study. In the new patients both doses resulted in a significant increase in height velocity (HV) and height SD score (SDS), with comparable bone maturation. After correction for the severity of GHD, the increase in HV SDS was significantly greater with 4 IU than with 2 IU (P less than 0.01). In the transfer patients HV, height SDS, and predicted adult height only increased significantly with 4 IU (P less than 0.05). Bone maturation was comparable for the two doses. There was a significant correlation between first year growth response and GH dose. In the new patients, the plasma insulin-like growth factor-I (IGF-I) concentration increased significantly without a significant difference between dosage groups. There was a positive correlation between growth response and increment of plasma IGF-I SDS. In new and transfer patients alike, above normal plasma IGF-I levels were observed, particularly with 4 IU. Hemoglobin-A1 remained constant with both GH doses in both groups, while cholesterol and LDL levels tended to decrease. In the new patients, the mean apolipoprotein-A1 level was lower than the control value after 1 yr on 4 IU GH. Treatment with 4 IU GH/m2.day led to a greater growth response than a dose of 2 IU in newly diagnosed as well as previously treated GHD patients. Bone maturation was comparable for both doses. No adverse effects were observed with the higher GH dose, but the long term effects on IGF-I and lipid metabolism need further attention.

Adolescent↗
PubMed1992

Hand bone growth during puberty and in Turner's syndrome.

Measurements were made on hand radiographs of normal girls and patients with Turner's syndrome. Normal girls going through puberty display increases in hand bone dimensions which are highly correlated with height and bone age. We report such changes in length and total bone width of metacarpal II (MCII) and proximal phalanx II (PPII), and in combined cortical thickness and cortical area of MCII. For the relative cortical area, the correlations are less pronounced. In comparison with controls of similar height, MCII of patients with Turner's syndrome has greater length and total bone width and combined cortical thickness. Turner patients treated with sex steroids undergo skeletal maturation as well as a rise in MCII relative cortical area (a measure of bone density), but fail to show a commensurate increase in MCII length and in MCII cortical area (a measure of bone mass). It is concluded that in untreated Turner patients, bone density as well as bone mass are normal for the (retarded) bone age, and that sex steroids which promote skeletal maturity likewise raise bone density but not bone mass. The (relative) insensitivity of bone mass and the lack of accelerated statural growth in response to administered sex steroids may be inborn characteristics of the Turner skeleton.

Adolescent↗
PubMed1992

Some skeletal dimensions of males with isolated gonadotrophin deficiency.

This is a retrospective study of stature and bone age before and during androgen substitution for hypogonadotrophic hypogonadism in 25 males. Before androgen treatment, stature tends to be low for chronological age but normal for bone age. Treatment results in normal final height. Growth in length of metacarpal bone II (MC II), measured on hand radiographs, mimics growth in height. From measurements of total bone width of MC II and combined cortical thickness of MC II, the cortical area (indicating bone mass) and the relative cortical area (indicating bone density) were calculated. Bone mass was well within the limits of a published control series, both before and during androgen treatment. Bone density, however, was, without exception, below the P50 for controls prior to androgen treatment, and increased only slightly during treatment. It is concluded that prepuberal deficiency of androgen, possibly in early infancy, causes a permanent defect in bone density which is only marginally corrected by later androgen treatment.

Adolescent↗
PubMed1991

Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure.

Stunted growth is a serious problem for children with chronic renal failure (CRF) despite normal endogenous growth hormone secretion and normal or elevated plasma concentrations of insulin-like growth factors (IGF) I and II. Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preceded or followed by 6 months of placebo injection. The patients had a full examination every 3 months. Sixteen children completed the study. Height velocity improved significantly with GH therapy (p less than 0.0001) and placebo (p less than 0.04), but the GH-induced height-velocity increase exceeded that of placebo by 2.9 cm per 6 months. There was a positive relationship between prestudy height velocity and height-velocity increase. Bone maturation was not affected. GH caused a significant increase in IGF-I and a moderate increase in IGF-II plasma concentrations. The pretreatment elevation of IGF-binding protein-1 decreased by almost 50% during GH therapy, while IGF-binding protein-3 increased significantly in concentration, although this increase was significantly smaller than the GH-induced increase in IGF-I. Fructosamine, lipid, and parathyroid concentrations remained constant. Renal function deterioration did not accelerate. Impressive height-velocity increase can be achieved with GH therapy in children with CRF and growth retardation without changes in renal function. Bone maturation appears unaffected suggesting improved final height. Treatment is best started before growth retardation becomes considerable.

Adolescent↗
PubMed1990

Growth of males with idiopathic hypopituitarism without growth hormone treatment.

We report auxologic data on 23 males with idiopathic hypopituitarism who grew up at a time when human growth hormone (GH) was not yet available, while receiving other appropriate hormonal substitution. We had reported previously that their adult heights were not significantly less than those of similar patients who had received GH. In the absence of GH the pubertal growth period was remarkably protracted, averaging 8.7 years for 19 patients during androgen substitution. Pubertal increment in height averaged 20.4 cm during induced puberty, a figure which compares favourably with those reported for GH-treated patients. This implies that GH does not increase the height gained during pubertal growth; the increase in the rate of growth appears to be off-set by a rise in the rate of skeletal maturation. During pubertal growth acceleration of growth of the skeleton seems unavoidably associated with acceleration of its maturation. Adult heights were significantly correlated with the heights at the time of onset of pubertal growth. This is evidence in favour of attempts to stimulate prepubertal growth much more than hitherto by earlier, higher, and more frequent doses of GH. It remains to be proved, however, that before puberty the processes of growth and maturation of the skeleton can be dissociated.

Adult↗
PubMed1989

A controlled trial of methionyl growth hormone therapy in prepubertal children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group.

Thirty short and slowly growing children with normal plasma growth hormone (GH) responses to standard provocation tests were randomly assigned to either a group (n = 20) undergoing treatment with methionyl GH (somatrem), 2 IU per m2 body surface s.c. daily, or a control group (n = 10). Twelve out of 18 children who completed the first year of treatment showed a height velocity increment of more than 2 cm/year. The mean (SD) growth velocity of the treatment group increased by 3.0 (1.9) cm/year over the first year, compared with -0.2 (0.7) cm/year in the control group. Neither parameters of endogenous GH secretion nor plasma IGF-I levels showed a significant correlation with the growth response. Of the auxological variables studied, pre-treatment growth velocity (r = -0.8) and the short-term height velocity increment (r = 0.7-0.9) showed significant correlations with the growth response in the first year of treatment. Somatrem therapy was without side effects, except in one child who developed anti-GH antibodies in combination with a poor growth response.

Body Height↗
PubMed1988

Methionyl human growth hormone in Turner's syndrome.

Sixteen girls with Turner's syndrome aged 7.9-15.2 years (bone ages 7.0-11.8 years) were given methionyl growth hormone (somatrem) 4 IU/m2 body surface daily, corresponding to 0.9 IU/kg/week. During one year of treatment their mean (SD) height velocity increased from 3.4 (0.9) to 7.2 (1.7) cm/year and height prediction from 148.2 (4.4) to 150.0 (4.4) cm. All the girls except one had a height velocity increment of more than 2 cm/year and these velocities are above the age references for girls with Turner's syndrome. The girl with a low growth response had antibodies against growth hormone with high binding capacity (3.7 U/l). The height velocity increment was inversely correlated with age and bone age, but this might be partly due to the somewhat higher dosage/m2 body surface and kg body weight that the younger patients were given because of the rounding off of the dose. The better results of our study compared with those of other workers who used similar dosages but did not give the drug as often suggest that giving it daily might have increased the growth response as it does in children deficient in growth hormone.

Adolescent↗
PubMed1987

The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty.

Twenty-five children (23 girls and 2 boys) with central precocious puberty were treated with the LH-RH agonist D-Ser (TBU)6-LHRH (1-9) EA (HOE 766, Buserelin) by daily subcutaneous injection for a period of 11-18 months. Eight girls and 2 boys previously treated with cyproterone acetate (CPA, 100-150 mg/m2 body surface per day) and the first seven newly diagnosed patients received 2 X 10 micrograms Buserelin/kg bodyweight per day for 1 week, followed by a maintenance therapy of 1 X 10 micrograms/kg per day. After an initial marked increase, oestrogen (E2) serum levels in girls and testosterone (T) values in boys decreased. After a treatment period of 6-20 weeks the patients received 2 X 20 micrograms Buserelin/kg per day for 1 week and thereafter a maintenance dosage of 20 micrograms/kg per day to obtain full suppression (i.e. E2 less than 50 pmol/l; T less than 1 nmol/l). The remaining eight patients started directly on 2 X 20 micrograms Buserelin/kg per day followed by 1 X 20 micrograms/kg per day. All eight girls with menarche before therapy had no further menses. In all girls there was a reduction of palpable breast tissue. Decrease of pubic hair development was observed in 3 girls, an increase was seen in 5 girls, whereas in the remaining 15 girls no change was observed. Both boys had a reduction of testicular volume and of pubic hair.(ABSTRACT TRUNCATED AT 250 WORDS)

Bone Development↗
PubMed1976

Puberty.

Explore the source record for details and available documents.

Adolescent↗
PubMedDate not supplied

Two-year results of treatment with methionyl human growth hormone in children with Turner syndrome. Dutch Growth Hormone Working Group.

Methionyl growth hormone (somatrem) in a daily dosage of 4 IU/m2 body surface area was administered to 16 girls with Turner syndrome. Low dose ethinyl estradiol (0.1 microgram/kg body weight) was added in girls aged 13 years or more. Mean (SD) height velocity increased from 3.4 (0.9) to 7.2 (1.7) and 5.3 (1.3) cm/year in the first and second year, respectively. Bone age advanced 1.8 years over 2 years and predicted adult height was increased. Apart from the occurrence of anti-GH antibodies there were no side effects. In conclusion, somatrem is an efficacious and safe therapy for short stature in Turner syndrome over a period of 2 years. Longer follow-up is needed before conclusions about its effect on final height can be drawn.

Adolescent↗